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AEROSOLIZED AND INTRAVENOUS RIBAVIRIN IN VIRAL RESPIRATORY
INFECTIONS IN IMMUNOCOMPROMISED PEDIATRIC PATIENTS
Therrien, R., Crisinel, P.-A., Gharbi, M., Raimbault, M., Buteau, C.
CHU Ste-Justine, Montreal, QC, Canada
Objective:To describe the use of ribavirin in immunocompromised
patients in a pediatric tertiary care center.
Patients and Methods: All immunocompromised patients who re-
ceived aerosolized or intravenous ribavirin for the treatment of a re-
spiratory viral infection from February 2001 through September
2007 were retrospectively included.
Results:Twenty-three patients were included, 11 boys and 12 girls.
The median age was 3.3 years (5.5 months to 17 years). Eighteen
patients (78%)were recipients of haematopoietic stem cell transplant
(HSCT). Two were treated for ALL, one had received a liver trans-
plant, one was HIV positive and one had a Fanconi syndrome.
Eleven patients (48%) received aerosolized ribavirin, 6 (26%) re-
ceived it intravenously and 6 (26%) received it by both routes but
not concomitantly. Mean ribavirin treatment was 30 days (4-105
days). Aerosolized ribavirin dose was 2 g over 2 hours every 8 hours
in 14/17 patients. For intravenous ribavirin, a median loading dose of
30 mg/kg (range 13-38) was used followed by maintenance doses
ranging from 4 to 23 mg/kg every 6 hours. Patients were treated
with ribavirin for the following infections: 11 respiratory syncytial vi-
rus, 14 parainfluenza virus (PIV) (9 PIV-3, 3 PIV-1, 2 PIV-2), 5 ad-
enovirus and one influenza A. Nine cases of viral co-infections were
observed. The mortality rate was 48% (11/23); 4 deaths (17%) were
related to the viral infection, 6 were due to pre-existent disease and
the cause of death remains uncertain in one case. The 4 patients
that died of viral infections were all HSCT patients. Fourteen pa-
tients (61%) received mechanical ventilation with a mean duration
of 19 days (2-55 days).
Conclusion:This is one of the largest series describing the use of in-
travenous ribavirin in immunocompromised pediatric patients with
respiratory virus infections. We found a 17% mortality rate linked
with the viral infection, which is comparable thanwhat has been pub-
lished previously.Table 1. Results of Cyclophosphamide plus Filgrastim Che-
momobilization in Multiple Myeloma Patients Following Le-
nalidomide Treatment
Group A
(LEN-treated pts)
Group B (non-LEN-
treated pts) p value
Total CD34+ cells  106/kg,
median (range)
7.43 (0-11.81) 9.15 (2.15-69.57) 0.159*
Total CD34+ cells  106/kg
after 2 leukapheresis, median
3.34 8.13 0.06*
Number of leukapheresis
sessions, median (range)
3 (1-5) 2 (1-5) 0.42*
Pts failing to collect minimum
CD34+ cells (%)
2 (17) 0 (0) 0.105**
*2-sided Mann-Whitney U test.
**Fisher’s exact test.546
COMPARATIVE COST-EFFECTIVENESS OF PLERIXAFOR PLUS GRANULO-
CYTE-COLONY STIMULATING FACTOR VERSUS CYCLOPHOSPHAMIDE
PLUS GRANULOCYTE-COLONY STIMULATING FACTOR FOR AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PATIENTS
WITH MULTIPLE MYELOMA
Campen, C.J.1,2, Yeager, A.M.2, Green, M.R.1,2, Armstrong, E.P.3
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Introduction: Chemotherapy + G-CSF and plerixafor (PLX) + G-
CSF effectively mobilize CD34+ cells for autologous stem cell trans-
plantation (ASCT), but are both associated with varying degrees of
efficacy, cost, and toxicity. We performed a retrospective study to
evaluate the differences in cost, effectiveness, and toxicity of first-
line mobilization of autologous peripheral blood stem cells (PBSC)
with cyclophosphamide (CY; 1.5-4 gm/m2) + G-CSF (n5 48) versus
PLX + G-CSF (n 5 19) in pts with multiple myeloma (MM).
Methods: Between 5/2006 and 7/2010 67 consecutive patients un-
dergoing mobilization for ASCT were retrospectively analyzed.
Comparative statistical analysis using minimum ($ 2 x 106) and op-
timal ($ 6 x 106) CD34+ cell/kg was performed. A decision analytic
model was also created to estimate the mean costs and effectiveness
rates for the two regimens. This model incorporated the minimum
acceptable CD34+ cell dose for autologous PBSC transplant and ad-
verse events such as clinically significant anemia, thrombocytopenia,
and hospital admissions for neutropenic fever. Costs were from the
perspective of a managed care organization and based on published
data. A treatment success for the model was defined as a minimum
CD34+ cells/kg of $ 2 x 106. We conducted a Monte Carlo simula-
tion of 1,000 cases.
Results: The minimum number of cells for successful PBSC mobi-
lization occurred in 46 of 48 pts (96%) in the CY group and in 19 of
19 pts (100%) in the PLX group (p0.366). Of the two patients thatfailed chemomobilization, both successfully collected with PLX +
G-CSF. Optimal cell dose collection occurred in 41/48 (85%) and
15/19 (79%) patients treated with CY and PLX respectively
(p0.519). A median of 2 collections were required for CY + G-CSF
versus 1 with PLX + G-CSF (p0.128). Seven patients mobilized
with CY + G-CSF were admitted for neutropenic fever. (p0.079 ver-
sus PLX). The mean costs were $14,149 and $13,087 for PLX + G-
CSF and CY + G-CSF, respectively. Overlap was observed in the
95% confidence intervals for both cost and effectiveness between
the two regimens.
Conclusion: Cyclophosphamide + G-CSF is equally cost-effective as
PLX+G-CSFamongMMpatients undergoing stemcellmobilization.
Plerixafor + G-CSF may provide opportunities for improved autolo-
gous PBSC transplant efficiency. This analysis does not consider pa-
tient, clinic, and provider convenience as well as patient quality of life.547
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MENT
Gerfen, A.D.1, Campen, C.J.2,3, Yeager, A.M.3, Green, M.R.2,3
1University of Arizona, Tucson, AZ; 2UniversityMedical Center, Tucson,
AZ; 3Arizona Cancer Center, Tucson, AZ
Background: No standard of care exists for treatment of multiple
myeloma (MM). Autologous stem cell transplant (ASCT) is the
current gold standard following induction therapy to improve over-
all survival. Lenalidomide (LEN) is used for treatment of MM
before ASCT, but antecedent exposure may impair autologous pe-
ripheral blood stem cell (PBSC) mobilization. Several strategies are
emerging to overcome LEN-induced impaired PBSC mobilization.
However, chemomobilization with cyclophosphamide (CTX) has
not been evaluated in this setting. CTX + filgrastim was investi-
gated to determine if LEN-associated mobilization impairment
can be abrogated.
Patients andMethods: 36 pts (group A 5 12 pts who received $ 2
cycles of LEN and group B 5 24 pts without LEN) from a single
center were analyzed retrospectively. Baseline characteristics were
matched (p . 0.05 for all variables). Three of 24 (13%) pts in
group B and 0 in group A received prior melphalan (p 5 0.09).
All pts received CTX (median group B, 1.5g/m2, range, 1.2-4; me-
dian group A, 3gm/m2; range, 1.5-4; (p 5 0.18)) and filgrastim
10mg/kg/day. Autologous PBSCs were collected by large volume
leukapheresis (3x blood volume). Mobilization failure was defined
as failure to collect at least 2x106/kg CD34+ cells. Primary out-
comes include total number of CD34+ cells collected and total
number of leukapheresis sessions. Secondary outcomes include fail-
ure to collect CD34+ cells and total CD34+ cells collected after
second leukapheresis.
Results (Table 1): Total median number of CD34+ cells collected
in group B 5 9.15x106/kg CD34+ cells (range, 2.15-69.57x106/kg
CD34+ cells) and group A 5 7.43x106/kg CD34+ cells (range, 0-
11.81x106/kg CD34+ cells) (p5 0.159).Median number of apheresis
sessions in group B 5 2 (range, 1-5) and group A 5 3 (range, 1-5)
(p 5 0.42). Two of 12 (17%) pts with antecedent LEN usage failedS349
